You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

488 Results
Document
Aug 2022
Document
Aug 2022
Guidelines and Advice
Status: In-Review
ID: GL END 3-24
Aug 2022
Statistical Reports
Statistical Reports
Document
Nov 2022
Document
Nov 2022
Document
Nov 2022
Document
Dec 2022
Document
Dec 2022
Document
Dec 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023

Pages